Merrill maintains Myriad at buy

Myriad Genetics Inc. was maintained by Merrill Lynch analyst David Munno at buy after reporting first quarter predictive medicine revenues of $26.8 million compared to the analyst's estimate of $24.6 million and consensus of $24.9 million. Based on better-than-expected demand and a 5% to 10% price increase, Merrill raised its predictive medicine revenue estimates to $100 million from $97 million for 2006 (June 30 year end), and to $133 million from $125 million for 2007. Shares of the Salt Lake City, Utah, biopharmaceutical company were up $0.44, or 1.64%, at $27.30 on volume of 341,630 shares versus the three-month running average of 413,076 shares. (Nasdaq: MYGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.